lncRNA HCG22 regulated cell growth and metastasis of papillary thyroid cancer via negatively modulating miR-425-5p.

Endokrynologia Polska Pub Date : 2024-01-01 DOI:10.5603/ep.97425

Xuepeng Cao, Chuang Ma, Yang Wu, Jianyuan Huang

{"title":"lncRNA HCG22 regulated cell growth and metastasis of papillary thyroid cancer via negatively modulating miR-425-5p.","authors":"Xuepeng Cao, Chuang Ma, Yang Wu, Jianyuan Huang","doi":"10.5603/ep.97425","DOIUrl":null,"url":null,"abstract":"Introduction: Papillary thyroid cancer (PTC) is a common malignant tumour in the endocrine system with increasing incidence. LncRNA HCG22 (HCG22) was noticed to be dysregulated in PTC, but its specific function and mechanism remain unknown. The function of HCG22 and its underlying molecular mechanism was investigated to evaluate its potential as a biomarker for PTC.Material and methods: The expression of HCG22 was detected in PTC cells (TPC-1, SNU790, GLAG-66, and BCPAP) and normal thyroid cells (Nthy-ori) using real time quantative polymerase chain reaction (RT-qPCR). HCG22 and miR-425-5p were regulated by cell transfection. The cell proliferation and metastasis were assessed by CCK8 and Transwell assay.Results: HCG22 was upregulated in PTC cells, of which the knockdown suppressed the proliferation, migration, and invasion of PTC cells. miR-425-5p was downregulated in PTC cells, which was negatively regulated by HCG22. Silencing miR-425-5p could reverse the inhibitory effect of HCG22 knockdown on the cellular processes of PTC.Conclusions: HCG22 served as a tumour promoter in PTC cells, which regulated cell proliferation and metastasis via negatively regulating miR-425-5p.","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endokrynologia Polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ep.97425","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Papillary thyroid cancer (PTC) is a common malignant tumour in the endocrine system with increasing incidence. LncRNA HCG22 (HCG22) was noticed to be dysregulated in PTC, but its specific function and mechanism remain unknown. The function of HCG22 and its underlying molecular mechanism was investigated to evaluate its potential as a biomarker for PTC.

Material and methods: The expression of HCG22 was detected in PTC cells (TPC-1, SNU790, GLAG-66, and BCPAP) and normal thyroid cells (Nthy-ori) using real time quantative polymerase chain reaction (RT-qPCR). HCG22 and miR-425-5p were regulated by cell transfection. The cell proliferation and metastasis were assessed by CCK8 and Transwell assay.

Results: HCG22 was upregulated in PTC cells, of which the knockdown suppressed the proliferation, migration, and invasion of PTC cells. miR-425-5p was downregulated in PTC cells, which was negatively regulated by HCG22. Silencing miR-425-5p could reverse the inhibitory effect of HCG22 knockdown on the cellular processes of PTC.

Conclusions: HCG22 served as a tumour promoter in PTC cells, which regulated cell proliferation and metastasis via negatively regulating miR-425-5p.

查看原文本刊更多论文

lncRNA HCG22通过负调控miR-425-5p调控甲状腺乳头状癌的细胞生长和转移

导言甲状腺乳头状癌（PTC）是内分泌系统中常见的恶性肿瘤，发病率呈上升趋势。人们注意到，LncRNA HCG22（HCG22）在PTC中存在失调，但其具体功能和机制仍不清楚。本研究对HCG22的功能及其潜在的分子机制进行了研究，以评估其作为PTC生物标志物的潜力：采用实时定量聚合酶链反应（RT-qPCR）检测 HCG22 在 PTC 细胞（TPC-1、SNU790、GLAG-66 和 BCPAP）和正常甲状腺细胞（Nthy-ori）中的表达。HCG22和miR-425-5p受细胞转染调控。CCK8和Transwell试验评估了细胞的增殖和转移：结果：HCG22在PTC细胞中上调，敲除HCG22可抑制PTC细胞的增殖、迁移和侵袭。沉默miR-425-5p可以逆转HCG22敲除对PTC细胞过程的抑制作用：结论：HCG22是PTC细胞中的肿瘤启动子，通过负调控miR-425-5p调节细胞增殖和转移。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endokrynologia Polska

CiteScore

0.60

自引率

0.00%

发文量